[go: up one dir, main page]

MX2019011281A - Compuestos de dinucleotidos ciclicos modificados. - Google Patents

Compuestos de dinucleotidos ciclicos modificados.

Info

Publication number
MX2019011281A
MX2019011281A MX2019011281A MX2019011281A MX2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A
Authority
MX
Mexico
Prior art keywords
cyclic dinucleotide
modified cyclic
dinucleotide compounds
compounds
modified
Prior art date
Application number
MX2019011281A
Other languages
English (en)
Inventor
Oost Thorsten
Fleck Martin
Carotta Sebastian
Andreas KUTTRUFF Christian
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019011281A publication Critical patent/MX2019011281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)

Abstract

Compuestos de la Fórmula (I) (ver fórmula) en donde la Base1 y la Base2 como se definen en la reivindicación 1 son moduladores de STING.
MX2019011281A 2017-03-22 2018-03-16 Compuestos de dinucleotidos ciclicos modificados. MX2019011281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17162392 2017-03-22
PCT/EP2018/056656 WO2018172206A1 (en) 2017-03-22 2018-03-16 Modified cyclic dinucleotide compounds

Publications (1)

Publication Number Publication Date
MX2019011281A true MX2019011281A (es) 2019-11-01

Family

ID=58412904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011281A MX2019011281A (es) 2017-03-22 2018-03-16 Compuestos de dinucleotidos ciclicos modificados.

Country Status (20)

Country Link
US (1) US10392419B2 (es)
EP (1) EP3601313B1 (es)
JP (2) JP6742534B2 (es)
KR (1) KR20190130612A (es)
CN (1) CN110382515B (es)
AR (1) AR111247A1 (es)
AU (1) AU2018239468A1 (es)
BR (1) BR112019017812A2 (es)
CA (1) CA3056008A1 (es)
CL (1) CL2019002590A1 (es)
CO (1) CO2019010023A2 (es)
EA (1) EA201992209A1 (es)
IL (1) IL268799A (es)
JO (1) JOP20190218A1 (es)
MX (1) MX2019011281A (es)
PE (1) PE20191556A1 (es)
PH (1) PH12019502155A1 (es)
SG (1) SG11201908567UA (es)
TW (1) TW201842919A (es)
WO (1) WO2018172206A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017524A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
JP7235512B2 (ja) * 2016-06-24 2023-03-08 バイオジェン・エムエイ・インコーポレイテッド キャッピング工程を有さないチオール化オリゴヌクレオチドの合成
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111989338A (zh) * 2018-03-27 2020-11-24 勃林格殷格翰国际有限公司 修饰的环二核苷酸化合物
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020117625A1 (en) * 2018-12-07 2020-06-11 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3891166A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CA3137119A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
JP7604396B2 (ja) 2019-05-10 2024-12-23 武田薬品工業株式会社 抗体薬物複合体
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN120324366A (zh) * 2019-10-07 2025-07-18 总医院公司 肺表面活性物质-仿生纳米颗粒的组合物和方法
JPWO2021206158A1 (es) 2020-04-10 2021-10-14
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20220111028A1 (en) 2020-10-14 2022-04-14 Boehringer Ingelheim International Gmbh Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP1740192B1 (en) 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
WO2014093936A1 (en) * 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
MX365661B (es) 2012-12-19 2019-06-10 Univ Texas Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
KR20170129802A (ko) * 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
WO2017027645A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2018009466A1 (en) * 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة

Also Published As

Publication number Publication date
SG11201908567UA (en) 2019-10-30
CN110382515B (zh) 2023-03-03
KR20190130612A (ko) 2019-11-22
US20180273578A1 (en) 2018-09-27
CO2019010023A2 (es) 2019-09-30
US10392419B2 (en) 2019-08-27
CL2019002590A1 (es) 2020-01-24
PH12019502155A1 (en) 2020-07-06
WO2018172206A1 (en) 2018-09-27
EP3601313A1 (en) 2020-02-05
CA3056008A1 (en) 2018-09-27
JP6742534B2 (ja) 2020-08-19
CN110382515A (zh) 2019-10-25
TW201842919A (zh) 2018-12-16
AU2018239468A1 (en) 2019-09-12
BR112019017812A2 (pt) 2020-03-31
JOP20190218A1 (ar) 2019-09-22
EP3601313B1 (en) 2021-03-10
PE20191556A1 (es) 2019-10-24
EA201992209A1 (ru) 2020-03-16
JP2020203887A (ja) 2020-12-24
JP2020514389A (ja) 2020-05-21
IL268799A (en) 2019-10-31
AR111247A1 (es) 2019-06-19

Similar Documents

Publication Publication Date Title
PH12019502155A1 (en) Modified cyclic dinucleotide compounds
PH12019500706A1 (en) Cyclic dinucleotide compounds
PH12019502870A1 (en) Small molecule modulators of human sting
ZA201805009B (en) Stable inoculant compositions and methods for producing same
MX2020009347A (es) Picolinamidas como fungicidas.
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12019502646A1 (en) Pyrazole magl inhibitors
ZA201507627B (en) P2x7 modulators
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
GB2547402A (en) Prevention and treatment of microbial infections
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
DOP2013000016A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
PH12018502556A1 (en) Cosmetic base including amide alcohol, and cosmetic
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
EP4566666A3 (en) Compositions and methods for modulating factor ix function
SG10201808383UA (en) Cyclic apelin analogs
PH12018501585B1 (en) Novel pyrrolidine derivatives
MY173966A (en) A cell-based composition and use thereof for treatment of acute stroke
MY171690A (en) A cell-based composition and use thereof for treatment of end-stage ischemic cardiomyopathy